HEXACATH Obtains one of the World first MDR certification for a Class III Coronary Stent Medical Device.
HEXACATH is proud to announce the certification of its TITAN OPTIMAX (bioactive coronary stent coated with Titanium-Nitride-Oxide) according to the New European Regulation (EU) 2017/745 for CE marking.
Le Quotidien du Médecin – 6 décembre 2018
Moins de thromboses et de récidives d’infarctus avec les stents bioactifs recouverts de Titane-NO par rapport aux stents actifs.
VIDEO CSC 2018 – 30 novembre 2018
Entrevista al Dr. Joan Anton Gómez Hospital « Estudio TIDES-ACS, Stent BIOACTIVO en el SCA, Hexacath » – CSC 2018.
Cardiologie Pratique – 1er septembre 2018
Le congrès EuroPCR a fourni l’opportunité de présenter les derniers résultats obtenus avec le stent bioactif de 3e génération TiTAN OPTIMAX©.
Cardio Online – 13 juin 2018
Dans le monde très concurrentiel des stents coronaires, le stent TITAN OPTIMAX© de la société française Hexacath est en train de se tailler la part du lion.
Cardio Online – 8 juin 2018
TIDES-ACS étudiait le stent bio actif vs stent actif dans le contexte de syndrome coronaire aigü (SCA) avec un recul de 18 mois, et une analyse en supériorité.
DAIC – 31 May 2018
Diagnostic and Interventional Cardiology.
Optimax TiNO-coated stent displayed better safety outcomes at 18 months without compromising target lesion revascularization.
euroPCR – 24 May 2018
TIDES-ACS trial: Titanium-Nitride-Oxide (TINO) coated stent demonstrated superiority to bioabsorbable polymer Everolimus-Eluting Stent (EES), for patients presenting with Acute Coronary Syndrome (ACS).
PCR Online – 24 May 2018
Clinical outcomes with new DES.
Session comprising selected EuroPCR 2018 Late-Breaking Trial submissions.
The Daily Wire – 23 May 2018
Until now, the prognostic role of PCI in patients with chronic coronary syndromes has been unclear, which has led to questions about its efficacy.
euroPCR – 23 May 2018
« Optimax-BAS should be in the Guidelines with
Class 1 and Level A recommendation in MI patients. »
Pasi P. Karjalainen
PCR Online – 12 May 2018
TiTAN OPTIMAX Bio Active Stent: The New Benchmark in ACS!
Demonstrated Safety Superiority vs. the Best-in-class DES
Cardiologie Pratique – 1er novembre 2017
Actualité Pharma.
Cardiovascular News – 1st September 2017
During a late-breaking science session at the European Society of Cardiology (ESC) congress (26–30 August, Barcelona, Spain), Pim Tonino (Heart center Catharina Hospital, Eindhoven, the Netherlands) reported that outcomes with a titanium-nitride-oxide coated stent (Optimax, Hexacath) is non-inferior to those of a everolimus-eluting stent with a biodegradable polymer (Synergy, Boston Scientific) in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI).
ESC – 26 August 2017
Study results : Titanium-Nitride-Oxide (TiNO) coated stent is non-inferior to bioabsorbable polymer everolimus-eluting stent (EES), for patients presenting with acute coronary syndrome (ACS).
Cardiologie Pratique – 30 septembre 2014
Le stent OPTIMAX est la troisième génération des stents recouverts de TiNO.
AsiaPCR – 12 January 2012
A Prospective, Randomised and Multicentre Trial Comparing Titan2 Bio Active Stent (BAS) and Xience V Drug Eluting Stent (DES): The BASE‐ACS Trial.
EuroPCR – 20 May 2011
One Year Clinical Outcome of the 2000 Patients Enrolled in the Coronary Angioplasty Acute Myocardial Infarction Titan2 Bio Active Stent Registry: The CATS-AMI Registry.
EuroPCR – 18 May 2011
ESC – 20 May 2009
The latest results of the multicenter prospective Randomized Controlled Trial TITAX AMI have been presented at the occasion of the Late Coronary Breaking Trials during EuroPCR 2009.
